Epsilon M&A Deal Report - Rocamed SAM

Transaction Multiples for the Valuation of Private Companies

Private Group led by 21 Invest > Rocamed SAM

Announced Date : 02 August 2024

Type : LBO (Leverage Buy Out)

Deal Value : Yes

Acquirer : Private Group led by 21 Invest

Target: Rocamed SAM

Target Country: Monaco

Sector of activity : Health, Pharmaceuticals & Biotechnology

Business Description :

> Founded in 2002, Rocamed is a medical device company specializing in sterile single-use solutio ...

No EMAT : 122117

Transaction multiples available

	EV/Sales	EV/Gross Profit	EV/EBITDA	EV/EBIT	Eq/PBT	P/E	Price to Book
Historic
Current

: Multiple available

n.s : Multiple calculated, but not significant

Rating *

Source: Epsilon Research / EMAT

Comparable Transactions

Number of EMAT Reports : (Health, Pharmaceuticals & Biotechnology) = 1245

Example of comparable transactions on EMAT (same sub-sector):

Date	Acquirer	Target	Country	Multiples	See details
07/02/2025	Private Group led by LBO France	Hemodia	France	**
12/10/2023	Simago France	GRIM 37 (Grim+)	France	*

Source: Epsilon Research / EMAT

View Report

This report is accessible on EMAT, the reference database for private company acquisition multiples

Example of EMAT Report : click here

View Complete Report

About Epsilon Research

Epsilon Research is an independent research and financial analysis bureau, and the reference source of transaction multiples for the valuation of private companies through its EMAT database.

Sectors covered by our analysts

Studies & indices published by Epsilon Research Register to receive (free) publications updates

EMAT Report

Each EMAT Report includes the detailed analysis of the transaction: deal rationale and structure, target business lines and financials (restated), valuation multiples (calculation and analysis).

Subscribe to EMAT database